Post-approval studies (Phase 4)Not Yet RecruitingNCT07587658
What this trial is testing
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
Who this might be right for
Chronic Obstructive Pulmonary Disease (COPD)
Regeneron Pharmaceuticals 754